Meet ApplyKite Twin, the application assistant that learns with you

Meet your Twin, it learns with you

Your Twin learns with you

Launch week codes:30% off annual Pro20% off monthly Pro

Ends in00h00m00s

Michael W. M Kühn

Professor of Medicine

University Medical Center of the Johannes Gutenberg University Mainz

Germany

Research Interests

Explore related searches

Professors in Germany Professors in Cell Biology Cell Biology professors in Germany

Articles (17)

Year:

2026

Year:

2026

Year:

2026

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Collaborators (11)

Vladimir Lazarevic

Lund University

SWEDEN

View details

Arnold Ganser

Professor emeritus

Hannover Medical School

GERMANY

View details

Florian Perner

Research Group Leader

Hannover Medical School

GERMANY

View details

Tamara Jacqueline Luck

University of Helsinki

FINLAND

View details

Véronique De Mas

Institut Universitaire du Cancer de Toulouse

FRANCE

View details

Florian Heidel

Professor, Director

Universitätsmedizin Greifswald

GERMANY

View details

John F. DiPersio

Director, Center for Gene and Cellular Immunotherapy

Washington University in St. Louis

UNITED STATES

View details

Stephane De Botton

Institut Gustave Roussy

FRANCE

View details

David Dickens

Division Chief

Nemours Children's Clinic

UNITED STATES

View details

Niklas Landberg

Lund University

SWEDEN

View details

Elke Krueger

Director

University Medicine Greifswald

GERMANY

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Michael W. M Kühn

Research Interests

Explore related searches

Articles (17)

Intensive Chemotherapy and Tyrosine Kinase Inhibitor in Patients with De Novo BCR::ABL1+ Acute Myeloid Leukemia

Inhibition of p300/CREBBP catalytic activity drives context-dependent transcriptional activation in AML

Menin inhibition enhances graft-versus-leukemia effects by T-cell activation and endogenous retrovirus induction in AML.

The evolving landscape of epigenetic target molecules and therapies in myeloid cancers: focus on acute myeloid leukemia and myeloproliferative neoplasms

Tailoring intensive and less-intensive treatment in acute myeloid leukemia.

Menin inhibition with revumenib for NPM1-mutated relapsed or refractory acute myeloid leukemia: the AUGMENT-101 study.

Therapeutic targeting of chromatin alterations in leukemia and solid tumors.

Acute resistance to BET inhibitors remodels compensatory transcriptional programs via p300 coactivation.

Targeting the Menin-KMT2A interaction in leukemia: Lessons learned and future directions.

Impact of myelodysplasia-related and additional gene mutations in intensively treated patients with NPM1-mutated AML.

The Menin story in acute myeloid leukaemia—The road to success

Measurable residual disease monitoring in AML with FLT3-ITD treated with intensive chemotherapy plus midostaurin

Refinement of the prognostic impact of somatic CEBPA bZIP domain mutations in acute myeloid leukemia: Results of the AML Study Group (AMLSG).

Immunoproteasome function maintains oncogenic gene expression in KMT2A-complex driven leukemia.

Menin inhibitor ziftomenib (KO-539) synergizes with drugs targeting chromatin regulation or apoptosis and sensitizes acute myeloid leukemia with MLL rearrangement or NPM1 mutation to venetoclax.

Epigenetic targeting to enhance acute myeloid leukemia-directed immunotherapy.

Intensive chemotherapy with or without gemtuzumab ozogamicin in patients with NPM1-mutated acute myeloid leukaemia (AMLSG 09-09): a randomised, open-label, multicentre, phase 3 trial.

Collaborators (11)

Vladimir Lazarevic

Arnold Ganser

Florian Perner

Tamara Jacqueline Luck

Véronique De Mas

Florian Heidel

John F. DiPersio

Stephane De Botton

David Dickens

Niklas Landberg

Elke Krueger

Make your next move.